General thoracic and cardiovascular surgery · 2026
Unilateral upper-lung field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis after lung cancer surgery: prolonged pleural effusion and pleural thickening as early postoperative indicators.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sekine Akimasa, Inafuku Kenji, Nishimura Masashi, Oda Tsuneyuki, Okuda Ryo, Arai Hiromasa, Koizumi Harumi, Saigusa Yusuke, Baba Tomohisa, Komatsu Shigeru, Hagiwara Eri, Iwasawa Tae, Ogura Takashi
Аннотация
BACKGROUND: Unilateral upper-lung field pulmonary fibrosis (upper-PF) can occur on the operative side after lung cancer surgery. It is reportedly associated with pleural effusion at 6 months post-surgery (PE-6mo), but the perioperative risk factors for PE-6mo and the cumulative incidence of upper-PF remain unclear.
METHODS: We retrospectively reviewed all patients with lung cancer who underwent radical surgical resection between 2008 and 2016. Perioperative characteristics were compared based on the presence of PE-6mo. The cumulative incidence of upper-PF in patients with PE-6mo was estimated using a competing risk analysis.
RESULTS: Of the 587 patients, 160 (27.2%) had PE-6mo. Multivariate analysis identified age > 70 years, body mass index < 22, thoracotomy, lobectomy, pulmonary apical cap, and adjuvant chemotherapy as independent risk factors for PE-6mo. Among 115 patients evaluable by chest CT for 2 years, 25 (21.7%) subsequently developed upper-PF (upper-PF group), while 90 did not (non-upper-PF group). The 3-, 5-, and 10-year cumulative incidences of upper-PF were 11.5%, 16.4%, and 24.6%. The upper-PF group more commonly had prolonged pleural effusion at 2 years than the non-upper-PF group (21/25 vs. 51/90, p = 0.018). Furthermore, pleural thickening was already evident at 6 months in the upper-PF group (15/25 vs. 18/90, P < 0.001) and thereafter. For patients with pleural thickening at 6 months, the 3-, 5-, and 10-year cumulative incidences of upper-PF were 24.2%, 35.0%, and 51.8%.
CONCLUSION: Prolonged pleural effusion with pleural thickening was a common phenomenon in patients who later developed upper-PF after surgery and may therefore be a strong postoperative indicator of upper-PF development.
METHODS: We retrospectively reviewed all patients with lung cancer who underwent radical surgical resection between 2008 and 2016. Perioperative characteristics were compared based on the presence of PE-6mo. The cumulative incidence of upper-PF in patients with PE-6mo was estimated using a competing risk analysis.
RESULTS: Of the 587 patients, 160 (27.2%) had PE-6mo. Multivariate analysis identified age > 70 years, body mass index < 22, thoracotomy, lobectomy, pulmonary apical cap, and adjuvant chemotherapy as independent risk factors for PE-6mo. Among 115 patients evaluable by chest CT for 2 years, 25 (21.7%) subsequently developed upper-PF (upper-PF group), while 90 did not (non-upper-PF group). The 3-, 5-, and 10-year cumulative incidences of upper-PF were 11.5%, 16.4%, and 24.6%. The upper-PF group more commonly had prolonged pleural effusion at 2 years than the non-upper-PF group (21/25 vs. 51/90, p = 0.018). Furthermore, pleural thickening was already evident at 6 months in the upper-PF group (15/25 vs. 18/90, P < 0.001) and thereafter. For patients with pleural thickening at 6 months, the 3-, 5-, and 10-year cumulative incidences of upper-PF were 24.2%, 35.0%, and 51.8%.
CONCLUSION: Prolonged pleural effusion with pleural thickening was a common phenomenon in patients who later developed upper-PF after surgery and may therefore be a strong postoperative indicator of upper-PF development.